$3.52
3.83% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US03843E1047
Symbol
AQST
Sector
Industry

Aquestive Therapeutics, Inc. Stock price

$3.52
-1.64 31.78% 1M
+0.93 35.91% 6M
+1.50 74.26% YTD
+1.51 75.12% 1Y
-0.44 11.11% 3Y
-2.02 36.40% 5Y
-12.53 78.07% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.14 3.83%
ISIN
US03843E1047
Symbol
AQST
Sector
Industry

Key metrics

Market capitalization $320.95m
Enterprise Value $362.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.15
P/S ratio (TTM) P/S ratio 5.45
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 22.56%
Revenue (TTM) Revenue $58.90m
EBIT (operating result TTM) EBIT $-21.10m
Free Cash Flow (TTM) Free Cash Flow $-34.37m
Cash position $77.89m
EPS (TTM) EPS $-0.45
P/E forward negative
P/S forward 5.46
EV/Sales forward 6.16
Short interest 13.33%
Show more

Is Aquestive Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Aquestive Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

Buy
100%

Financial data from Aquestive Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
59 59
23% 23%
100%
- Direct Costs 18 18
16% 16%
31%
41 41
54% 54%
69%
- Selling and Administrative Expenses 43 43
31% 31%
72%
- Research and Development Expense 18 18
26% 26%
31%
-20 -20
3% 3%
-34%
- Depreciation and Amortization 1.04 1.04
18% 18%
2%
EBIT (Operating Income) EBIT -21 -21
4% 4%
-36%
Net Profit -35 -35
191% 191%
-60%

In millions USD.

Don't miss a Thing! We will send you all news about Aquestive Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aquestive Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
about 2 months ago
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Xometry's AI-driven procurement software in a specialized B2B marketplace shows high-growth potential to Bert Hochfeld, making it a promising investment. Grassroots Trading argues that Boston Scientific's acquisition of Axonics enhances its ...
Neutral
Seeking Alpha
about 2 months ago
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q3 2024 Earnings Call Transcript November 5, 2024 8:00 AM ET Company Participants Bennett Watson - IR, ICR Westwicke IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Steve Wargacki - CSO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler Francois Brisebois - Op...
Positive
Seeking Alpha
about 2 months ago
Aquestive Therapeutics specializes in innovative film-based medicines and epinephrine products & delivery. The company's PharmFilm and Adrenaverse platforms offer unique competitive advantages, making it a strong investment opportunity. A risk-adjusted valuation indicates that Aquestive is currently undervalued compared to its market price.
More Aquestive Therapeutics, Inc. News

Company Profile

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

Head office United States
CEO Daniel Barber
Employees 135
Founded 2004
Website www.aquestive.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today